PharmaZell Continues Expansion of Pharmaceutical Manufacturing Capacity in India

Sept. 19, 2010 - PRLog -- Vizag, India (September 2010) – PharmaZell GmbH, a European Contract Manufacturing Organization for active pharmaceutical ingredients and advanced intermediates, has once again expanded its manufacturing capabilities in India. In 2010, PharmaZell completed construction of a cGMP Kilo-lab at its R&D center in Vizag, India. This follows two other recent expansions in India. In 2007, PharmaZell built a commercial production plant in Vizag, India to produce the active pharmaceutical ingredient, Mesalamine.  In 2008, PharmaZell continued expanding in Vizag by building a state of the art R&D facility. This facility employs approximately 35 chemists who focus on chemical route and process development, analytical R&D and small scale synthesis.  

In 2007, PharmaZell expanded its European base by acquiring a fully integrated development and commercial production site from Sandoz in Copenhagen, Denmark. The site in Denmark has a particular focus on controlled substances. Its scientists there have expertise in lab development, pilot plant and commercial manufacturing under cGMP. “In the past three years PharmaZell has had three expansions in India while growing by acquisition in Europe. We have continued to grow our manufacturing capacity and expand our services to the pharmaceutical and biotechnology industries. We believe that our strong revenue growth and diverse customer base is positioning our company as a significant API manufacturer and service provider” said Wolfgang Burger, Ph.D., Managing Partner of PharmaZell.

About PharmaZell
PharmaZell is a European Contract Manufacturing Organization (CMO) that provides products and services to the pharmaceutical and biotech industries. PharmaZell performs custom synthesis and manufacturing of small molecule drug substances and advanced intermediates at the gram, kilogram and metric ton scales. The company provides a broad range of capabilities in chemistry, process research and development, process optimization, scale-up and commercialization as well comprehensive analytical and regulatory services for active pharmaceutical ingredients (APIs) in support of preclinical programs, clinical trials, and commercial production. PharmaZell also offers a diverse product portfolio of APIs and amino acids to the pharmaceutical, nutraceutical and food industries.

PharmaZell was founded in 1947 and was successfully spun off from Noveon/Lubrizol in 2006, through a management buyout. The company is headquartered in Raubling, Germany which is near the Munich area. A second production site was built in 1994 in Chennai, India, followed by expansions in Copenhagen, Denmark and Vizag India in 2007. PharmaZell has 500 employees located at the four sites in Europe and India. All four sites are fully compliant with current GMP regulations. The sites in Germany and Chennai have been inspected by the FDA and inspections of the sites in Copenhagen and Vizag, India are expected within the coming months.

Company Contact:
George Hlass, MBA
george.hlass@pharmazell.com
(919) 678-6858